Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KNSA |
---|---|---|
09:32 ET | 4221 | 19.73 |
09:34 ET | 1375 | 19.77 |
09:36 ET | 722 | 19.7882 |
09:38 ET | 100 | 19.775 |
09:39 ET | 330 | 19.8 |
09:43 ET | 907 | 19.78 |
09:45 ET | 843 | 19.66 |
09:50 ET | 500 | 19.67 |
09:56 ET | 433 | 19.71 |
09:57 ET | 122 | 19.73 |
10:01 ET | 921 | 19.71 |
10:03 ET | 139 | 19.675 |
10:12 ET | 100 | 19.6484 |
10:19 ET | 650 | 19.64 |
10:21 ET | 100 | 19.6 |
10:28 ET | 100 | 19.63 |
10:30 ET | 200 | 19.615 |
10:32 ET | 301 | 19.63 |
10:33 ET | 100 | 19.61 |
10:35 ET | 1500 | 19.62 |
10:37 ET | 100 | 19.635 |
10:39 ET | 557 | 19.58 |
10:42 ET | 526 | 19.59 |
10:44 ET | 1100 | 19.7 |
10:46 ET | 600 | 19.685 |
10:48 ET | 300 | 19.6648 |
10:50 ET | 8468 | 19.79 |
10:55 ET | 127 | 19.77 |
10:57 ET | 523 | 19.76 |
11:00 ET | 1539 | 19.7001 |
11:02 ET | 500 | 19.7 |
11:08 ET | 292 | 19.69 |
11:11 ET | 119 | 19.64 |
11:15 ET | 500 | 19.62 |
11:18 ET | 561 | 19.65 |
11:22 ET | 100 | 19.655 |
11:33 ET | 100 | 19.63 |
11:38 ET | 100 | 19.63 |
11:42 ET | 707 | 19.62 |
11:44 ET | 805 | 19.68 |
11:47 ET | 200 | 19.665 |
11:51 ET | 100 | 19.67 |
11:54 ET | 1299 | 19.63 |
11:56 ET | 300 | 19.63 |
12:02 ET | 114 | 19.6 |
12:03 ET | 100 | 19.61 |
12:07 ET | 679 | 19.59 |
12:09 ET | 332 | 19.58 |
12:12 ET | 200 | 19.61 |
12:14 ET | 798 | 19.6 |
12:23 ET | 2141 | 19.61 |
12:25 ET | 1075 | 19.61 |
12:27 ET | 100 | 19.6 |
12:30 ET | 300 | 19.59 |
12:32 ET | 202 | 19.57 |
12:39 ET | 100 | 19.5625 |
12:41 ET | 100 | 19.565 |
12:45 ET | 127 | 19.57 |
12:48 ET | 1702 | 19.625 |
12:50 ET | 200 | 19.625 |
12:57 ET | 879 | 19.61 |
01:03 ET | 2016 | 19.58 |
01:06 ET | 216 | 19.555 |
01:08 ET | 100 | 19.54 |
01:12 ET | 323 | 19.54 |
01:14 ET | 314 | 19.55 |
01:15 ET | 436 | 19.55 |
01:32 ET | 221 | 19.555 |
01:37 ET | 627 | 19.56 |
01:39 ET | 747 | 19.53 |
01:53 ET | 667 | 19.49 |
02:04 ET | 833 | 19.53 |
02:08 ET | 300 | 19.55 |
02:09 ET | 100 | 19.55 |
02:11 ET | 224 | 19.55 |
02:13 ET | 500 | 19.57 |
02:15 ET | 227 | 19.575 |
02:18 ET | 941 | 19.52 |
02:20 ET | 100 | 19.5 |
02:22 ET | 100 | 19.5 |
02:24 ET | 1105 | 19.4912 |
02:26 ET | 462 | 19.5 |
02:27 ET | 100 | 19.49 |
02:29 ET | 200 | 19.495 |
02:33 ET | 1438 | 19.46 |
02:38 ET | 600 | 19.45 |
02:40 ET | 100 | 19.445 |
02:42 ET | 144 | 19.46 |
02:45 ET | 200 | 19.47 |
02:51 ET | 936 | 19.47 |
02:54 ET | 100 | 19.48 |
03:03 ET | 100 | 19.46 |
03:05 ET | 1301 | 19.43 |
03:07 ET | 2127 | 19.43 |
03:09 ET | 400 | 19.422 |
03:14 ET | 206 | 19.43 |
03:16 ET | 219 | 19.44 |
03:20 ET | 308 | 19.46 |
03:21 ET | 200 | 19.46 |
03:25 ET | 110 | 19.47 |
03:27 ET | 200 | 19.45 |
03:30 ET | 200 | 19.44 |
03:32 ET | 600 | 19.45 |
03:34 ET | 5760 | 19.42 |
03:36 ET | 516 | 19.44 |
03:38 ET | 700 | 19.43 |
03:39 ET | 3442 | 19.41 |
03:41 ET | 831 | 19.42 |
03:43 ET | 400 | 19.39 |
03:45 ET | 749 | 19.4 |
03:48 ET | 900 | 19.42 |
03:50 ET | 200 | 19.42 |
03:52 ET | 2502 | 19.45 |
03:54 ET | 1427 | 19.46 |
03:56 ET | 1532 | 19.44 |
03:57 ET | 1212 | 19.44 |
03:59 ET | 41651 | 19.48 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kiniksa Pharmaceuticals Ltd | 1.4B | 228.6x | --- |
Dynavax Technologies Corp | 1.4B | 220.2x | --- |
MiMedx Group Inc | 1.2B | 20.9x | --- |
Ginkgo Bioworks Holdings Inc | 1.9B | -2.0x | --- |
BioCryst Pharmaceuticals Inc | 1.2B | -5.0x | --- |
MannKind Corp | 1.2B | 192.1x | --- |
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.4B |
---|---|
Revenue (TTM) | $301.8M |
Shares Outstanding | 70.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.34 |
EPS | $0.09 |
Book Value | $6.23 |
P/E Ratio | 228.6x |
Price/Sales (TTM) | 4.6 |
Price/Cash Flow (TTM) | 127.9x |
Operating Margin | -10.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.